Cargando…

Internalization and trafficking of CSPG-bound recombinant VAR2CSA lectins in cancer cells

Proteoglycans are proteins that are modified with glycosaminoglycan chains. Chondroitin sulfate proteoglycans (CSPGs) are currently being exploited as targets for drug-delivery in various cancer indications, however basic knowledge on how CSPGs are internalized in tumor cells is lacking. In this stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Chris Kedong, Nelepcu, Irina, Hui, Desmond, Oo, Htoo Zarni, Truong, Sarah, Zhao, Sarah, Tahiry, Zakir, Esfandnia, Shaghayegh, Ghaidi, Fariba, Adomat, Hans, Dagil, Robert, Gustavsson, Tobias, Choudhary, Swati, Salanti, Ali, Sorensen, Poul H., Al Nakouzi, Nader, Daugaard, Mads
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866492/
https://www.ncbi.nlm.nih.gov/pubmed/35197518
http://dx.doi.org/10.1038/s41598-022-07025-6
Descripción
Sumario:Proteoglycans are proteins that are modified with glycosaminoglycan chains. Chondroitin sulfate proteoglycans (CSPGs) are currently being exploited as targets for drug-delivery in various cancer indications, however basic knowledge on how CSPGs are internalized in tumor cells is lacking. In this study we took advantage of a recombinant CSPG-binding lectin VAR2CSA (rVAR2) to track internalization and cell fate of CSPGs in tumor cells. We found that rVAR2 is internalized into cancer cells via multiple internalization mechanisms after initial docking on cell surface CSPGs. Regardless of the internalization pathway used, CSPG-bound rVAR2 was trafficked to the early endosomes in an energy-dependent manner but not further transported to the lysosomal compartment. Instead, internalized CSPG-bound rVAR2 proteins were secreted with exosomes to the extracellular environment in a strictly chondroitin sulfate-dependent manner. In summary, our work describes the cell fate of rVAR2 proteins in tumor cells after initial binding to CSPGs, which can be further used to inform development of rVAR2-drug conjugates and other therapeutics targeting CSPGs.